Li Sisi, Huang Xiao-Ting, Wang Meng-Yao, Chen Dong-Ping, Li Ming-Yi, Zhu Yan-Yi, Yu Yi, Zheng Lu, Qi Bin, Liu Jin-Quan
Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Front Oncol. 2021 Jun 24;11:653005. doi: 10.3389/fonc.2021.653005. eCollection 2021.
Radiotherapy is one of the standard treatments for cervical cancer and head and neck cancer. However, the clinical efficacy of this treatment is limited by radioresistance. The discovery of effective prognostic biomarkers and the identification of new therapeutic targets have helped to overcome the problem of radioresistance. In this study, we show that in the context of PIK3CA mutation or amplification, high expression of fascin actin-bundling protein 1 (FSCN1) (using the median as the cut-off value) is associated with poor prognosis and radiotherapy response in cancer patients. Silencing FSCN1 enhances radiosensitivity and promotes apoptosis in cancer cells with PIK3CA alterations, and this process may be associated with the downregulation of YWHAZ. These results reveal that FSCN1 may be a key regulator of radioresistance and could be a potential target for improving radiotherapy efficacy in cervical cancer and head and neck cancer patients with PIK3CA alterations.
放射治疗是宫颈癌和头颈癌的标准治疗方法之一。然而，这种治疗的临床疗效受到放射抗性的限制。有效预后生物标志物的发现和新治疗靶点的鉴定有助于克服放射抗性问题。在本研究中，我们表明，在PIK3CA突变或扩增的情况下，肌动蛋白成束蛋白1（FSCN1）高表达（以中位数作为临界值）与癌症患者的预后不良和放疗反应相关。沉默FSCN1可增强放射敏感性并促进PIK3CA改变的癌细胞凋亡，这一过程可能与14-3-3ζ的下调有关。这些结果表明，FSCN1可能是放射抗性的关键调节因子，并且可能是提高PIK3CA改变的宫颈癌和头颈癌患者放疗疗效的潜在靶点。
